Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Applying wargames to real-world policies-Response.

Reddie AW, Goldblum BL, Reinhardt J, Lakkaraju K, Epifanovskaya L, Nacht M.

Science. 2019 Mar 29;363(6434):1406-1407. doi: 10.1126/science.aaw7260. No abstract available.

PMID:
30923214
2.

Next-generation wargames.

Reddie AW, Goldblum BL, Lakkaraju K, Reinhardt J, Nacht M, Epifanovskaya L.

Science. 2018 Dec 21;362(6421):1362-1364. doi: 10.1126/science.aav2135. No abstract available.

PMID:
30573619
3.

iPAD or PADi-'tablets' with therapeutic disease potential?

Lewis HD, Nacht M.

Curr Opin Chem Biol. 2016 Aug;33:169-78. doi: 10.1016/j.cbpa.2016.06.020. Epub 2016 Jun 30. Review.

PMID:
27372273
4.

The Tec Kinase-Regulated Phosphoproteome Reveals a Mechanism for the Regulation of Inhibitory Signals in Murine Macrophages.

Tampella G, Kerns HM, Niu D, Singh S, Khim S, Bosch KA, Garrett ME, Moguche A, Evans E, Browning B, Jahan TA, Nacht M, Wolf-Yadlin A, Plebani A, Hamerman JA, Rawlings DJ, James RG.

J Immunol. 2015 Jul 1;195(1):246-56. doi: 10.4049/jimmunol.1403238. Epub 2015 May 29.

5.

In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing.

Tjin Tham Sjin R, Lee K, Walter AO, Dubrovskiy A, Sheets M, Martin TS, Labenski MT, Zhu Z, Tester R, Karp R, Medikonda A, Chaturvedi P, Ren Y, Haringsma H, Etter J, Raponi M, Simmons AD, Harding TC, Niu D, Nacht M, Westlin WF, Petter RC, Allen A, Singh J.

Mol Cancer Ther. 2014 Jun;13(6):1468-79. doi: 10.1158/1535-7163.MCT-13-0966. Epub 2014 Apr 10.

6.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, van Kalken D, Chaturvedi P, Niu D, Nacht M, Petter RC, Westlin W, Lin K, Jaw-Tsai S, Raponi M, Van Dyke T, Etter J, Weaver Z, Pao W, Singh J, Simmons AD, Harding TC, Allen A.

Cancer Discov. 2013 Dec;3(12):1404-15. doi: 10.1158/2159-8290.CD-13-0314. Epub 2013 Sep 24.

7.

Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans.

Evans EK, Tester R, Aslanian S, Karp R, Sheets M, Labenski MT, Witowski SR, Lounsbury H, Chaturvedi P, Mazdiyasni H, Zhu Z, Nacht M, Freed MI, Petter RC, Dubrovskiy A, Singh J, Westlin WF.

J Pharmacol Exp Ther. 2013 Aug;346(2):219-28. doi: 10.1124/jpet.113.203489. Epub 2013 May 24.

PMID:
23709115
8.

Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα.

Nacht M, Qiao L, Sheets MP, St Martin T, Labenski M, Mazdiyasni H, Karp R, Zhu Z, Chaturvedi P, Bhavsar D, Niu D, Westlin W, Petter RC, Medikonda AP, Singh J.

J Med Chem. 2013 Feb 14;56(3):712-21. doi: 10.1021/jm3008745. Epub 2013 Feb 5.

PMID:
23360348
9.

Tumor endothelial marker 7 (TEM-7): a novel target for antiangiogenic therapy.

Bagley RG, Rouleau C, Weber W, Mehraein K, Smale R, Curiel M, Callahan M, Roy A, Boutin P, St Martin T, Nacht M, Teicher BA.

Microvasc Res. 2011 Nov;82(3):253-62. doi: 10.1016/j.mvr.2011.09.004. Epub 2011 Sep 17.

PMID:
21958527
10.

Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine.

Hagel M, Niu D, St Martin T, Sheets MP, Qiao L, Bernard H, Karp RM, Zhu Z, Labenski MT, Chaturvedi P, Nacht M, Westlin WF, Petter RC, Singh J.

Nat Chem Biol. 2011 Jan;7(1):22-4. doi: 10.1038/nchembio.492. Epub 2010 Nov 28.

PMID:
21113170
11.

Netrin-4 regulates angiogenic responses and tumor cell growth.

Nacht M, St Martin TB, Byrne A, Klinger KW, Teicher BA, Madden SL, Jiang Y.

Exp Cell Res. 2009 Mar 10;315(5):784-94. doi: 10.1016/j.yexcr.2008.11.018. Epub 2008 Dec 6.

PMID:
19094984
12.

Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248.

Bagley RG, Rouleau C, St Martin T, Boutin P, Weber W, Ruzek M, Honma N, Nacht M, Shankara S, Kataoka S, Ishida I, Roberts BL, Teicher BA.

Mol Cancer Ther. 2008 Aug;7(8):2536-46. doi: 10.1158/1535-7163.MCT-08-0050.

13.

Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.

Rouleau C, Roy A, St Martin T, Dufault MR, Boutin P, Liu D, Zhang M, Puorro-Radzwill K, Rulli L, Reczek D, Bagley R, Byrne A, Weber W, Roberts B, Klinger K, Brondyk W, Nacht M, Madden S, Burrier R, Shankara S, Teicher BA.

Mol Cancer Ther. 2006 Feb;5(2):219-29.

14.

Identification of a binding partner for the endothelial cell surface proteins TEM7 and TEM7R.

Nanda A, Buckhaults P, Seaman S, Agrawal N, Boutin P, Shankara S, Nacht M, Teicher B, Stampfl J, Singh S, Vogelstein B, Kinzler KW, St Croix B.

Cancer Res. 2004 Dec 1;64(23):8507-11.

15.

Alterations in vascular gene expression in invasive breast carcinoma.

Parker BS, Argani P, Cook BP, Liangfeng H, Chartrand SD, Zhang M, Saha S, Bardelli A, Jiang Y, St Martin TB, Nacht M, Teicher BA, Klinger KW, Sukumar S, Madden SL.

Cancer Res. 2004 Nov 1;64(21):7857-66. Erratum in: Cancer Res. 2004 Dec 1;64(23):8794.

16.

Vascular gene expression in nonneoplastic and malignant brain.

Madden SL, Cook BP, Nacht M, Weber WD, Callahan MR, Jiang Y, Dufault MR, Zhang X, Zhang W, Walter-Yohrling J, Rouleau C, Akmaev VR, Wang CJ, Cao X, St Martin TB, Roberts BL, Teicher BA, Klinger KW, Stan RV, Lucey B, Carson-Walter EB, Laterra J, Walter KA.

Am J Pathol. 2004 Aug;165(2):601-8.

17.

Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways.

Jiang Y, Zhang W, Kondo K, Klco JM, St Martin TB, Dufault MR, Madden SL, Kaelin WG Jr, Nacht M.

Mol Cancer Res. 2003 Apr;1(6):453-62.

18.

Molecular characteristics of non-small cell lung cancer.

Nacht M, Dracheva T, Gao Y, Fujii T, Chen Y, Player A, Akmaev V, Cook B, Dufault M, Zhang M, Zhang W, Guo M, Curran J, Han S, Sidransky D, Buetow K, Madden SL, Jen J.

Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15203-8.

19.

Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer.

Nacht M, Ferguson AT, Zhang W, Petroziello JM, Cook BP, Gao YH, Maguire S, Riley D, Coppola G, Landes GM, Madden SL, Sukumar S.

Cancer Res. 1999 Nov 1;59(21):5464-70.

20.
21.

Mutations in the p53 and SCID genes cooperate in tumorigenesis.

Nacht M, Strasser A, Chan YR, Harris AW, Schlissel M, Bronson RT, Jacks T.

Genes Dev. 1996 Aug 15;10(16):2055-66.

22.

Identification and cloning of EI24, a gene induced by p53 in etoposide-treated cells.

Lehar SM, Nacht M, Jacks T, Vater CA, Chittenden T, Guild BC.

Oncogene. 1996 Mar 21;12(6):1181-7.

PMID:
8649819
23.
24.

[The man in blue].

Nacht M.

Rev Int Hist Psychanal. 1993;6:389-94. French.

PMID:
11640438
25.
26.

Use of electromyographic biofeedback during the acute phase of spinal cord injury: a case report.

Nacht MB, Wolf SL, Coogler CE.

Phys Ther. 1982 Mar;62(3):290-4. No abstract available.

PMID:
7063528
27.

Veterans Administration Prosthetics Center report.

Nacht M.

Bull Prosthet Res. 1979 Fall;16(2):441-500. No abstract available.

PMID:
160262
28.

[Clinical studies on the effect of niflumic acid in stomatology].

Dechaume M, Péri G, Nacht M.

Rev Stomatol Chir Maxillofac. 1968 Jun;69(4):315-7. French. No abstract available.

PMID:
5245454

Supplemental Content

Support Center